The spectrum of apocrine lesions of the breast

Advances in Anatomic Pathology

Volumn 11, Issue 1, 2004, Pages 1-9

  O'Malley, F P ^a   Bane, A L ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Apocrine; Breast; Complex sclerosing lesion; Cysts; Ductal carcinoma in situ; Molecular alterations; Sclerosing adenosis

Indexed keywords

APOCRINE GLAND; BREAST TUMOR; FEMALE; HUMAN; PAGET NIPPLE DISEASE; PATHOLOGY; REVIEW;

APOCRINE GLANDS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS;

EID: 84883587857     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-200401000-00001     Document Type: Article

References (65)

1. O'Malley. Non-invasive apocrine lesions of the breast. Current Diagnostic Pathology. In press.
2. Dixon JM, Lumsden AB, Miller WR. The relationship of cyst type to risk factors for breast cancer and the subsequent development of breast cancer in patients with breast cystic disease. Eur J Cancer Clin Oncol. 1985;21:1047-1050. (Pubitemid 15227463)
3. Bruzzi P, Dogliotti L, Naldoni C, et al. Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. Br Med J. 1997;314:925-928. (Pubitemid 27140215)
4. Dixon JM, McDonald C, Miller WR. Risk of breast cancer in women with palpable breast cysts: a prospective study. Lancet. 1999;353:1742-1745. (Pubitemid 29240372)
5. Devitt JE, To T, Miller AB. Risk of breast cancer in women with breast cysts. Can Med Assoc J. 1992;147:45-49.
6. Jones BM, Bradbeer JW. The presentation and progress of macroscopic breast cysts. Br J Surg. 1980;67:669-671. (Pubitemid 11226626)
7. Haagensen CD. Diseases of the Breast. Philadelphia:WBSaunders, 1981.
8. Roberts MM, Jones V, Elton RA, et al. Risk of breast cancer in women with history of benign disease of the breast. Br Med J (Clin Res Ed). 1984;288:275-278. (Pubitemid 14085696)
9. Bundred NJ, West RR, Dowd JO, et al. Is there an increased risk of breast cancer in women who have had a breast cyst aspirated? Br J Cancer. 1991;64:953-955.
10. Haagensen CD, Bodian CA. Haagensen DE Jr. Breast Cancer Risk and Detection. Philadelphia: WB Saunders, 1981.
11. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-151. (Pubitemid 15192861)
12. Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. [see comments] Arch Pathol Lab Med. 1998;122:1053-1055. (Pubitemid 29009396)
13. Page DL, Dupont WD, Jensen RA. Papillary apocrine change of the breast: associations with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 1996;5:29-32.
14. Eusebi V, Casadei GP, Bussolati G, et al. Adenomyoepithelioma of the breast with a distinctive type of apocrine adenosis. Histopathology. 1987;11:305-315. (Pubitemid 17038278)
15. Kiaer H, Nielsen B, Paulsen S, et al. Adenomyoepithelial adenosis and low-grade malignant adenomyoepithelioma of the breast. Virchows Arch A Pathol Anat Histopathol. 1984;405:55-67. (Pubitemid 15209411)
16. Simpson JF, Page DL, Dupont WD. Apocrine adenosis-a mimic of mammary carcinoma. Surg Pathol. 1990;3:289-299.
17. Carter DJ, Rosen PP. Atypical apocrine metaplasia in sclerosing lesions of the breast: a study of 51 patients. Mod Pathol. 1991;4:1-5.
18. Wells CA, McGregor GI, Makunura CN, et al. Apocrine adenosis: a precursor of aggressive breast cancer. J Clin Pathol. 1995;48:737-742.
19. Raju U, Zarbo RJ, Kubus J, et al. The histologic spectrum of apocrine brest proliferations: A comparative study of morphology and DNA content by image analysis. Hum Pathol. 1993;24:173-181. (Pubitemid 23066596)
20. Seidman JD, Ashton M, Lefkowitz M. Atypical apocrine adenosis of the breast: a clinicopathologic study of 37 patients with 8.7-year follow-up. Cancer. 1996;77:2529-2537. (Pubitemid 26000009)
21. Endoh Y, Tamura G, Kato N, et al. Apocrine adenosis of the breast: clonal evidence of neoplasia. Histopathology. 2001;38:221-224. (Pubitemid 32862731)
22. Page DL, Simpson JF. What is apocrine adenosis, anyway? Histopathology. 2001;39:433-434.
23. Selim AG, El-Ayat G, Wells CA. c-erbB2 oncoprotein expression, gene amplification, and chromosome 17 aneusomy in apocrine adenosis of the breast. J Pathol. 2000;191:138-142. (Pubitemid 30394890)
24. Moriya T, Sakamoto K, Sasano H, et al. Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases. Mod Pathol. 2000;13:13-18. (Pubitemid 30077899)
25. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712. (Pubitemid 19147683)
26. Press MF. Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894-2904.
27. Selim AG, El-Ayat G, Wells CA. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. Virchows Arch. 2002;441:449-455. (Pubitemid 35430459)
28. Eusebi V, Damiani S, Losi L, et al. Apocrine differentiation in breast epithelium. Adv Anat Pathol. 1997;4:139-155.
29. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol. 1992;23:1095-1097.
30. O'Malley FP, Page DL, Nelson EH, et al. Ductal carcinoma in situ of the breast with apocrine cytology: definition of a borderline category. Hum Pathol. 1994;25:164-168. (Pubitemid 24079637)
31. Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod Pathol. 1994;7:813-818.
32. Durham JR, Fechner RE. The histologic spectrum of apocrine lesions of the breast. Am J Clin Pathol. 2000;113(5 Suppl 1):S3-S18.
33. Scott MA, Lagios MD, Axelsson K, et al. Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis [see comments]. Hum Pathol. 1997;28:967-973. (Pubitemid 27355558)
34. The Consensus Conference Committee. Consensus conference on the classification of ductal carcinoma in situ. [see comments]. Cancer. 1997;80:1798-1802.
35. Leal C, Henrique R, Monteiro P, et al. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Hum Pathol. 2001;32:487-493. (Pubitemid 32506518)
36. Azzopardi JG. Problems in Breast Pathology. Philadelphia: WB Saunders, 1979.
37. Mossler JA, Barton TK, Brinkhous AD, et al. Apocrine differentiation in human mammary carcinoma. Cancer. 1980;46:2463-2471. (Pubitemid 11253708)
38. Eusebi V, Betts C, Haagensen DE Jr, et al. Apocrine differentiation in lobular carcinoma of the breast: a morphologic, immunologic, and ultrastructural study. Hum Pathol. 1984;15:134-140. (Pubitemid 14194129)
39. Rosen PP. Rosen's Breast Pathology. 2 ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001.
40. Haagensen CD. Diseases of the breast. 3 ed. Philadelphia: W.B. Saunders, 1986.
41. Mazoujian G, Pinkus GS, Davis S, et al. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol. 1983;110:105-112. (Pubitemid 13147256)
42. Eusebi V, Millis RR, Cattani MG, et al. Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Am J Pathol. 1986;123:532-541. (Pubitemid 16090148)
43. Wick MR, Lillemoe TJ, Copland GT, et al. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol. 1989;20:281-287. (Pubitemid 19081966)
44. Papotti M, Eusebi V, Gugliotta P, et al. Immunohistochemical analysis of benign and malignant papillary lesions of the breast. Am J Surg Pathol. 1983;7:451-461. (Pubitemid 13006791)
45. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol. 1992;23:655-662.
46. Pagani A, Sapino A, Eusebi V, et al. PIP/GCDFP-15 gene expression and apocrine differentiation in carcinomas of the breast. Virchows Arch. 1994;425:459-465.
47. Le D. V, Zangerle PF, Collette J et al. Immunohistochemistry of a component protein of the breast cystic disease fluid with mol. wt 15,000. Eur J Cancer Clin Oncol. 1985;21:715-725.
48. Miller WR, Shivas AA, Franchimont P, et al. Breast gross cystic disease protein 15 in human breast cancer in culture. Eur J Cancer Clin Oncol. 1988;24:223-228. (Pubitemid 18051190)
49. Ahmed A. Atlas of ultrastructure of human diseases. New York: Churchill Livingstone, 1978.
50. Mossler JA, Barton TK, Brinkhous AD, et al. Apocrine differentiation in human mammary carcinoma. Cancer. 1980;46:2463-2471. (Pubitemid 11253708)
51. Abati AD, Kimmel M, Rosen PP. Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am J Clin Pathol. 1990;94:371-377. (Pubitemid 20316558)
52. d'Amore ES, Terrier-Lacombe MJ, Travagli JP, et al. Invasive apocrine carcinoma of the breast: a long term follow-up study of 34 cases. Breast Cancer Res Treat. 1988;12:37-44.
53. Schmitt FC, Soares R, Seruca R. Bilateral apocrine carcinoma of the breast. Molecular and immunocytochemical evidence for two independent primary tumours. Virchows Arch. 1998;433:505-509. (Pubitemid 28561181)
54. Frable WJ, Kay S. Carcinoma of the breast. Histologic and clinical features of apocrine tumors. Cancer. 1968;21:756-763.
55. Bryant J. Male breast cancer: a case of apocrine carcinoma with psammoma bodies. Hum Pathol. 1981;12:751-753.
56. Kopans DB, Nguyen PL, Koerner FC, et al. Mixed form, diffusely scattered calcifications in breast cancer with apocrine features. Radiology. 1990;177:807-811.
57. Gilles R, Guinebretiere JM, Toussaint C, et al. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology. 1994;191:633-638. (Pubitemid 24177877)
58. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract. 1997;193:753-758.
59. Sapp M, Malik A, Hanna W. Hormone receptor profile of apocrine lesions of the breast. Breast J. 2003;9:335-336. (Pubitemid 36927422)
60. Moinfar F, Okcu M, Tsybrovskyy O, et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer. 2003;98:703-711. (Pubitemid 36959265)
61. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nature Med. 1997;3:227-230. (Pubitemid 27064710)
62. Lakhani SR, Slack DN, Hamoudi R, et al. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lab Invest. 1996;74:129-135. (Pubitemid 26041015)
63. Lininger RA, Zhuang Z, Man Y, et al. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast. Mod Pathol. 1999;12:1083-1089. (Pubitemid 30033539)
64. Washington C, Dalbegue F, Abreo F, et al. Loss of heterozygosity in fibrocystic change of the breast: genetic relationship between benign proliferative lesions and associated carcinomas. Am J Pathol 2000;157:323-329. (Pubitemid 30641748)
65. Jones C, Damiani S, Wells D, et al. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am J Pathol. 2001;158:207-214. (Pubitemid 32096486)